Despite tremendous gains in the molecular understanding of exocrine pancreatic cancer,
the prognosis for this disease remains very poor, largely because of delayed disease …

Surgical resection combined with systemic chemotherapy is the cornerstone of treatment for
patients with localized pancreatic cancer. Upfront surgery is considered suboptimal in cases …

Importance Fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) and
gemcitabine plus nanoparticle albumin-bound (nab)–paclitaxel (GA) are first-line …

Background: Neoadjuvant therapy (NAT) is used in borderline resectable/locally advanced
(BR/LA) pancreatic ductal adenocarcinoma (PDAC). Anatomic imaging (CT/MRI) poorly …

Importance The benefit of adjuvant chemotherapy after resection of pancreatic cancer
following neoadjuvant combination treatment with folinic acid, fluorouracil, irinotecan, and …

Background Neoadjuvant chemotherapy (NAC) is an integral part of preoperative treatment
for patients with borderline resectable/locally advanced (BR/LA) pancreatic ductal …

Introduction: Vascular resection remains a subject of debate in the management of
Pancreatic Ductal Adenocarcinoma (PDAC). These French recommendations were drafted …

Objective: We sought to identify potential radiologic and serologic markers of pancreatic
tumor response to therapy, using pathologic major response (pMR) as the objective …

Most patients diagnosed with pancreatic cancer are classified as nonoperative candidates
based on the contemporary guidelines of resectability. The advent of more potent control of …

BACKGROUND. Imaging biomarkers of response to neoadjuvant therapy (NAT) for
pancreatic ductal adenocarcinoma (PDA) are needed to optimize treatment decisions and …